Therapeutic Sequencing in ALK+ NSCLC
M Elsayed, P Christopoulos - Pharmaceuticals, 2021 - mdpi.com
Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC) is a
model disease for the use of targeted pharmaceuticals in thoracic oncology. Due to higher …
model disease for the use of targeted pharmaceuticals in thoracic oncology. Due to higher …
Detecting resistance to therapeutic ALK inhibitors in tumor tissue and liquid biopsy markers: an update to a clinical routine practice
P Hofman - Cells, 2021 - mdpi.com
The survival of most patients with advanced stage non-small cell lung cancer is prolonged
by several months when they are treated with first-and next-generation inhibitors targeting …
by several months when they are treated with first-and next-generation inhibitors targeting …
Prognostic value of TP53 concurrent mutations for EGFR-TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
K Qin, H Hou, Y Liang, X Zhang - BMC cancer, 2020 - Springer
Background The prognostic significance of TP53 concurrent mutations in patients with
epidermal growth factor receptor (EGFR)-or anaplastic lymphoma kinase (ALK)-mutated …
epidermal growth factor receptor (EGFR)-or anaplastic lymphoma kinase (ALK)-mutated …
[PDF][PDF] Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
R Dziadziuszko, S Peters, T Mok, DR Camidge… - Clinical Cancer …, 2022 - AACR
Introduction: We retrospectively assessed prognostic value of circulating cell-free DNA
(cfDNA) using data from the phase III ALEX study in treatment-naïve, advanced ALK+ …
(cfDNA) using data from the phase III ALEX study in treatment-naïve, advanced ALK+ …
Oligoprogressive non-small-cell lung cancer under treatment with PD-(L) 1 inhibitors
S Rheinheimer, CP Heussel, P Mayer, L Gaissmaier… - Cancers, 2020 - mdpi.com
Oligoprogression (OPD) of non-small-cell lung cancer (NSCLC) occurs in approximately half
of patients under targeted compounds (TKI) and facilitates use of regional therapies that can …
of patients under targeted compounds (TKI) and facilitates use of regional therapies that can …
Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell …
VCA Caponio, G Troiano, I Adipietro… - British journal of …, 2020 - nature.com
Background Mutations of the tumour-suppressor gene TP53 are the most frequent somatic
genomic alterations in head and neck squamous cell carcinoma (HNSCC). However, it is not …
genomic alterations in head and neck squamous cell carcinoma (HNSCC). However, it is not …
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
AK Angeles, P Christopoulos, Z Yuan, S Bauer… - NPJ Precision …, 2021 - nature.com
Targeted kinase inhibitors improve the prognosis of lung cancer patients with ALK
alterations (ALK+). However, due to the emergence of acquired resistance and varied …
alterations (ALK+). However, due to the emergence of acquired resistance and varied …
Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
A Tanimoto, S Matsumoto, S Takeuchi, S Arai… - Clinical Cancer …, 2021 - AACR
Purpose: In ALK-rearranged non–small cell lung cancer (NSCLC), impacts of concomitant
genetic alterations on targeted therapies with ALK-tyrosine kinase inhibitors (ALK-TKI) are …
genetic alterations on targeted therapies with ALK-tyrosine kinase inhibitors (ALK-TKI) are …
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung …
L Mezquita, A Swalduz, C Jovelet… - JCO precision …, 2020 - ascopubs.org
PURPOSE Liquid biopsy specimen genomic profiling is integrated in non–small-cell lung
cancer (NSCLC) guidelines; however, data on the clinical relevance for ALK/ROS1 …
cancer (NSCLC) guidelines; however, data on the clinical relevance for ALK/ROS1 …
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
S Dietz, P Christopoulos, Z Yuan, AK Angeles, L Gu… - …, 2020 - thelancet.com
Background Targeted therapies (TKI) have improved the prognosis of ALK-rearranged lung
cancer (ALK+ NSCLC), but clinical courses vary widely. Early identification and molecular …
cancer (ALK+ NSCLC), but clinical courses vary widely. Early identification and molecular …